Presence and Duration of Atrial Fibrillation Detected by Continuous Monitoring: Crucial Implications for the Risk of Thromboembolic Events

AF and the Risk of Thromboembolic Events. Introduction: Asymptomatic atrial fibrillation (AF) can expose patients to the risk of stroke. The primary objective of this study was to assess the incidence of thromboembolic events in relationship with CHADS₂ (congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, and prior stroke, or transient ischemic attack) score and AF presence/duration. The secondary objective was to compare intermittent versus continuous monitoring strategies. Methods and Results: Data from patients with an implanted pacemaker and a history of AF were analyzed. Thromboembolic risk was quantified through CHADS₂ score. Three AF groups were considered: patients with <5‐minutes AF on 1 day (AF‐free); patients with >5‐minutes AF on 1 day but <24 hours (AF‐5 minutes); patients with AF episodes >24 hours (AF‐24 hours). Monitoring strategies involving 24‐hour Holter, 1‐week Holter, and 30‐day Holter were simulated. Data from 568 patients continuously monitored for 1 year were analyzed: 171 (30%) had CHADS₂ score = 0; 269 (47%) had CHADS₂ score = 1; 111 (20%) had CHADS₂ score = 2; and 17 (3%) had CHADS₂ score ≥ 3. During follow‐up, 14 patients (2.5%) had an ischemic thromboembolic event. AF‐24 hours patients numbered 223 (39.2%); AF‐5 minutes, 179 (31.5%); and AF‐free, 29.2%. By combining AF presence/duration with CHADS₂ score, two subpopulations with markedly different risks of events (0.8% vs 5%, P = 0.035) were identified, the former corresponding to AF‐free with CHADS₂≤2, or AF‐5 minutes with CHADS₂≤1, or AF‐24 hours with CHADS₂= 0. The mean sensitivity in detecting an AF episode lasting >5 minutes was 44.4%, 50.4%, and 65.1% for 24‐hour Holter, 1‐week Holter, and 1‐month Holter monitoring, respectively. Conclusion: In patients with recurrent AF episodes, risk stratification for thromboembolic events can be improved by combining CHADS₂ score with AF presence/duration. (J Cardiovasc Electrophysiol, Vol. 20, pp. 241‐248, March 2009)     

The incidence and role of actinomyces in recurrent acute tonsillitis

A histological and bacteriological study of 129 pairs of tonsils from patients with recurrent acute tonsillitis showed actinomyces to be present in 29.5%. The organism, however, was also present in 40% of tonsils from 10 patients with no history of tonsillar disease. In neither of these groups was there any specific evidence of tissue reaction to actinomyces nor was there a male preponderance as in clinical actionomycosis. The presence of actinomyces in the tonsil was not favoured by the concurrence of β-lactamase producing bacteria. These data indicate that actinomyces does not have a causal role in recurent acute tonsillitis.     

DEVELOPMENTAL DELAY: INTERVENTION PROCEDURES

This article examines developmental delay and the implications of such disorders. Firstly, developmental delay is defined and the normal developmental process is briefly described. The types of problems which ensue if this process is interrupted or disturbed are then viewed. The need and importance of early intervention procedures are substantiated by experimental evidence, and the present tendency for late diagnosis, and the reasons for it, are also considered. Finally, Occupational Therapy as a discipline, it is argued, has a role to play in the treatment of children with developmental delay as well as providing support for parents.     

Treatment of Ventricular and Supraventricular Tachyarrhythmias by Transcutaneous Cardiac Pacing

The efficacy of noninvasive transcutaneous cardiac pacing (TCP) in the treatment of tachyarrhythmic events was tested in 24 patient: 14 with ventricular tachycardia, seven with supraventricular tachycardia and three with atrial flutter. Six (42.9%) ventricular tachycardias were interrupted: in two of the ten patients on whom underdrive pacing was attempted and in all four cases in which overdrive stimulation was possible. Five of the six supraventricular tachycardias utilizing an atrioventricular bypass tract were interrupted, while the TCP was unsuccessful on the only patient with atrioventricular nodal reentrant tachycardia. TCP failed to interrupt the arrhythmia in the three cases of atrial flutter. No clinically significant untoward effects (in particular tachycardia acceleration or ventricular fibrillation) were observed, except for a tolerable thumping sensation on the chest during pacing. In four patients, TCP effects on cardiac activation was evaluated by endocavitary recording: while the mean ventricular threshold was 70 mA, atrial capture was possible on only two patients at a current intensity of 140 and 150 mA. We consider our preliminary experience with TCP in the treatment of tachycardias encouraging. The technique was easily and rapidly usable and it was immediately successful in the majority of atrioventricular reentrant tachycardias and in a relevant percentage of ventricular tachycardias. In this latter setting TCP was mostly effective in the slower tachycardias where overdrive pacing was possible. A further experience with devices provided by higher pacing rates is warranted.     

DL and D Sotalol Decrease Defibrillation Energy Requirements

We examined the acute effects of intravenous DL and D sotalol on the energy requirements for internal defibrillation (DF) in 44 dogs anesthetized with pentobarbital (n = 18), enflurane (n = 8), and fentanyl (n = 18). Multiple shocks of varying energies were applied through left and right ventricular epicardial patch electrodes to relate delivered energy to percent success in DF. The energies required for 50% success in DF (E) were estimated by logistic regression. DL or D sotalol was administered in a loading (4 mg/kg over 10 min) and maintenance (1.5 mg/kg/hr) infusion and the energy--success curve was again measured 30 minutes after drug administration. The effect of DL and D sotalol on E50 was compared to controls given saline. Both DL and D sotalol significantly lowered E50 by 16% +/- 14% (P less than 0.05) and 24.5% +/- 8.2% (P less than 0.05), respectively, in fentanyl anesthetized animals; this was accompanied by a 22% +/- 8% (P less than 0.05) and 16% +/- 5% (P less than 0.01) increase in ventricular effective refractory period (VERP), respectively. In pentobarbital anesthetized dogs, DL and D sotalol decreased E50 by 16% +/- 27% (P = ns) and 11% +/- 16% (P less than 0.05), respectively, and were associated with a 23% +/- 5% (P less than 0.01) and 12 +/- 4% (P less than 0.05) prolongation of VERP. DL and D sotalol decrease defibrillation energy requirements, possibly as a result of their Class III antiarrhythmic drug action.